Docket No. 268519US0PCT Preliminary Amendment

IN THE CLAIMS

Please amend the claims as follows:

Claims 1-3 (Canceled).

Claim 4 (Currently Amended): A diagnostic kit for eating disorders comprising as an

active ingredient an antibody against brain-derived neurotrophic factor and a labeling agent

as the components.

Claim 5 (Currently Amended): The diagnostic kit for eating disorders according to

claim 4, for wherein said diagnostic kit is capable of measuring the concentration of a brain-

derived neurotrophic factor in blood in patients.

Claim 6 (Currently Amended): The diagnostic kit for eating disorders according to

elaim 4 or 5, claim 4, comprising an antibody against brain-derived neurotrophic factor and a

labeled antibody against brain-derived neurotrophic factor.

Claim 7 (Currently Amended): A method for detecting one or more eating disorders

which comprises measuring the concentration of a brain-derived neurotrophic factor in blood

in animals.

Claim 8 (Currently Amended): The method for detecting eating disorders according

to claim 7, which comprises measuring the concentration of a brain-derived neurotrophic

factor with an antibody against brain-derived neurotrophic factor.

2

Docket No. 268519US0PCT Preliminary Amendment

Claim 9 (Currently Amended): The method for detecting eating disorders according to claim 7, which comprises measuring the concentration of a brain-derived neurotrophic factor with an antibody against brain-derived neurotrophic factor and a labeled antibody against brain-derived neurotrophic factor.

Claim 10 (Currently Amended): A method for detecting a therapeutic agent of <u>one or more</u> eating disorders, which comprises measuring the concentration of a brain-derived neurotrophic factor in blood in animals.

Claims 11-12 (Canceled).

Claim 13 (New): The diagnostic kit according to claim 5, comprising an antibody against brain-derived neurotrophic factor and a labeled antibody against brain-derived neurotrophic factor.